At UCB, everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” We are a global biopharmaceutical company focused on severe diseases of the immune system and central nervous system. UCB operates in approximately 40 countries. We invest 25% of revenue in cutting-edge scientific research to meet unmet needs. UCB’s global pipeline includes treatments for lupus, osteoporosis and other autoimmune and cognitive disorders.
Andrew Craigie Circle